Connect for Cancer Prevention Study (Connect)
Launched by NATIONAL CANCER INSTITUTE (NCI) · Oct 29, 2020
Trial Information
Current as of June 21, 2025
Recruiting
Keywords
ClinConnect Summary
The Connect for Cancer Prevention Study is a large research project aimed at understanding the causes of cancer and finding new ways to prevent it. Researchers want to learn how our lifestyle, genetics, and health history can influence cancer risk. This study is open to 200,000 adults aged 30 to 70 who are receiving health care from one of the participating health systems and have never had cancer (though those with a history of non-melanoma skin cancer or certain conditions that may increase cancer risk can still join).
If you choose to participate, you can sign up online and will need to complete an informed consent process to ensure you understand what the study involves. Participants will answer health surveys a few times a year and provide samples of blood, urine, and saliva every two to three years. You may also share information from health trackers, like fitness apps. The study will last for many years, allowing researchers to gather valuable information, and you can decide to leave the study at any time. For more information, you can visit cancer.gov/connectstudy.
Gender
ALL
Eligibility criteria
- * INCLUSION CRITERIA:
- Due to the minimal risk nature of this protocol, all individuals interested and able to participate in Connect for Cancer Prevention, who meet the eligibility criteria at time of initial study invitation, will be able to participate. In order to be eligible to participate in this study, an individual must meet all of the following criteria:
- • Patients or members of participating IHCS at the time of enrollment
- • Age between 30 and 70 years old at study invitation
- • If an individual is determined to be ineligible at the time of enrollment due to age, the individual will be allowed to re-enroll at a later time once the recruit meets the age requirement. This includes recruits that did not meet the original age requirement of 40-65 years of age but now meet the updated age range of 30-70.
- EXCLUSION CRITERIA:
- An individual who meets any of the following criteria at time of initial study invitation will be excluded from participation in this study:
- • Individuals with a confirmed history of invasive cancer (other than non-melanoma skin cancer)
- • Individuals with known cognitive impairment documented in their medical record
About National Cancer Institute (Nci)
The National Cancer Institute (NCI) is a prominent component of the National Institutes of Health (NIH), dedicated to advancing cancer research and improving patient outcomes through innovative clinical trials. As a leading sponsor of cancer-related studies, NCI focuses on facilitating the development of new therapies, enhancing prevention strategies, and understanding the biology of cancer. The institute collaborates with academic institutions, healthcare providers, and industry partners to conduct rigorous clinical trials that aim to translate scientific discoveries into effective treatments. NCI’s commitment to fostering a robust research environment supports the mission to eliminate cancer as a major health problem.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Detroit, Michigan, United States
Chicago, Illinois, United States
Atlanta, Georgia, United States
Sioux Falls, South Dakota, United States
Chicago, Illinois, United States
Minneapolis, Minnesota, United States
Marshfield, Wisconsin, United States
Dallas, Texas, United States
Denver, Colorado, United States
Honolulu, Hawaii, United States
Chicago, Illinois, United States
Bethesda, Maryland, United States
Portland, Oregon, United States
Patients applied
Trial Officials
Nicolas A Wentzensen, M.D.
Principal Investigator
National Cancer Institute (NCI)
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials